Overview: Humog is a medication manufactured by Bharat Serums and Vaccines containing the active substance Human Menopausal Gonadotropin (hMG). It is a hormonal medication used primarily in assisted reproductive technology (ART) procedures, such as in vitro fertilization (IVF) and other fertility treatments. Humog works by stimulating the ovaries to produce eggs and is commonly prescribed for women with infertility issues due to ovulatory disorders.

Active Substance:

• Human Menopausal Gonadotropin (hMG): Humog contains hMG, which is a mixture of two gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). These hormones are naturally produced by the pituitary gland and play essential roles in regulating the menstrual cycle and fertility. In Humog, hMG is derived from the urine of postmenopausal women and purified for therapeutic use.

Indications: Humog (hMG) is primarily indicated for:

1. Assisted Reproductive Technology (ART): It is used in conjunction with other fertility medications to induce ovulation in women undergoing infertility treatment, such as IVF or intrauterine insemination (IUI).
2. Ovulatory Disorders: Humog may be prescribed for women with ovulatory disorders, such as polycystic ovary syndrome (PCOS), who have difficulty conceiving naturally due to irregular or absent ovulation.

Mechanism of Action: Human Menopausal Gonadotropin (hMG) exerts its therapeutic effects by mimicking the actions of endogenous FSH and LH in the body. FSH stimulates the growth and development of ovarian follicles, each containing an immature egg (oocyte). LH triggers the final maturation of the dominant follicle and induces ovulation, the release of the mature egg from the ovary.

Dosage and Administration: The dosage of Humog (hMG) is individualized based on the patient’s age, weight, ovarian reserve, and response to previous fertility treatments. It is typically administered via subcutaneous or intramuscular injection, with dosing regimens tailored to the specific fertility protocol being used. Treatment with Humog is usually initiated at the beginning of the menstrual cycle and continued for several days until the ovaries are adequately stimulated and follicular development is optimal.

Potential Side Effects: Common side effects associated with Humog may include:

• Ovarian hyperstimulation syndrome (OHSS), characterized by abdominal bloating, pelvic discomfort, nausea, and fluid retention (rare but serious).
• Multiple gestation (twins or higher-order multiples) due to the stimulation of multiple follicles and ovulation.
• Injection site reactions, such as redness, swelling, or bruising.
• Ovarian cysts, which may develop as a result of ovarian stimulation.
• Mood swings, fatigue, or headache.

Precautions:

• Humog should only be used under the supervision of a qualified healthcare provider experienced in fertility treatment.
• Patients undergoing treatment with Humog should be monitored closely with ultrasound and hormone level measurements to assess follicular growth and prevent complications such as OHSS.
• The risk of multiple gestation should be discussed with patients prior to initiating treatment, and appropriate counseling and management strategies should be implemented.

In conclusion, Humog contains Human Menopausal Gonadotropin (hMG), a hormonal medication used in fertility treatment to induce ovulation in women with ovulatory disorders. While effective in stimulating ovarian follicle growth and maturation, Humog carries risks of side effects and should be used cautiously under medical supervision.